A ransomware attack on eResearch Technology, the firm behind three-quarters of FDA drug approvals, slowed down clinical trials for several research facilities.
Biogen’s CPO, Susan Wise, shares how COVID-19 has impacted the company’s clinical trials and brought a difference in views of privacy being a consumer right versus a human right.
